正确理解新生血管性疾病的发病机制，合理行使抗新生血管药物治疗

Understanding the pathogenesis of various type in exudative AMD, using the rational therapy

血管内皮生长因子（VEGF）是眼内新生血管形成过程中起关键作用的中心环节，抗VEGF治疗是眼内新生血管性疾病治疗的突破点。抗新生血管药物玻璃体腔注入是一种安全、有效的治疗眼部新生血管性及渗出性疾病的方式，具有生物相容性好，价格低，玻璃体内半衰期较长，不需要频繁注射等优点；但目前缺乏多中心研究，其长期效果和安全性有待进一步临床验证。新生血管的病因、类型不同，治疗反应也不一样；同样的新生血管，治疗方式也不尽相同，需要正确理解新生血管性疾病的发病机制，合理选择治疗方式，努力探索安全、有效、经济、方便的治疗新方法。

Up-regulation of vascular endothelial growth factor （VEGF） is demonstrated to be a key role in formation process of intraocular neovascularization. Anti-VEGF treatment is the breakthrough of intraocular neovascular diseases therapy. Intravitreal injection of anti-neovascularization drug looks to be an effective method on ocular neovascular diseases which with the advantages of good biocompatibility, low prices and longer intravitreal half-time etc. However, at present, it lack of multi-center study; the long-term efficacy and the systematic safety needs the further clinical verification. Various types of CNV showed the different therapeutic reactions to either PDT or Anti-VEGF agent, the treatment methods for exudative AMD include laser, PDT, and drug like Triamcinolone Acetonide, several anti-VEGF preparations. Therefore, understanding the pathogenesis of neovascular AMD and choosing a reasonable therapeutic methods are necessary. We should try to explore a safe, effective, economic, new approach.